Regend Therapeutics   Report issue

For profit Phase 2
Founded: Suzhou China (2015)

Organization Overview

First Clinical Trial
2016
NCT02722642
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Regend Therapeutics | Regend Therapeutics Co.Ltd | Regend Therapeutics XLotus (Jiangxi) Co, Ltd.

Active Ingredients

Drugs in Phase 2 Trials (3)

bronchial basal cells (9 trials)

lung stem cells (2 trials)

regend001 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bronchiectasis (Phase 2)

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Interstitial (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Pulmonary Fibrosis (Phase 2)

Respiration Disorders (Phase 1)

Respiratory Tract Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 3